{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:06:00Z","timestamp":1780484760875,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02032-0","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:28:25Z","timestamp":1772000905000},"page":"2731-2746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pro-Synergistic Interaction of Farnesene and Daunorubicin Enhances Apoptotic Vulnerability in U87MG Glioblastoma Cells"],"prefix":"10.1007","volume":"84","author":[{"given":"Hatice","family":"KARATA\u015e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"ARSLAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara Esra","family":"MEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrkan","family":"BERBER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"T\u00dcRKEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Enes","family":"ARSLAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"10","key":"2032_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMOA043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., & Mirimanoff, R. O. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine, 352(10), 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMOA043330","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"2032_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., & Mirimanoff, R. O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology, 10(5), 459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"The Lancet Oncology"},{"issue":"6190","key":"2032_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/SCIENCE.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., & Bernstein, B. E. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York N Y), 344(6190), 1396. https:\/\/doi.org\/10.1126\/SCIENCE.1254257","journal-title":"Science (New York N Y)"},{"issue":"2","key":"2032_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., & Quaranta, V. (2019). Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Cell Systems, 8(2), 97\u2013108e16. https:\/\/doi.org\/10.1016\/j.cels.2019.01.003","journal-title":"Cell Systems"},{"issue":"2","key":"2032_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. (2010). Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Research, 70(2), 440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Research"},{"key":"2032_CR6","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/J.CRPHAR.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte, D., & Vale, N. (2022). Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Current Research in Pharmacology and Drug Discovery, 3, 100110. https:\/\/doi.org\/10.1016\/J.CRPHAR.2022.100110","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"key":"2032_CR7","doi-asserted-by":"publisher","unstructured":"Foucquier, J., & Guedj, M. (2015). Analysis of drug combinations: current methodological landscape. Pharmacology Research and Perspectives, 3(3). https:\/\/doi.org\/10.1002\/PRP2.149","DOI":"10.1002\/PRP2.149"},{"issue":"12","key":"2032_CR8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/NEUONC\/NOAA104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna, C., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., & Chalmers, A. J. (2020). Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), 1840. https:\/\/doi.org\/10.1093\/NEUONC\/NOAA104","journal-title":"Neuro-Oncology"},{"issue":"4","key":"2032_CR9","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.21873\/INVIVO.12470","volume":"35","author":"K Hwang","year":"2021","unstructured":"Hwang, K., Lee, J. H., Kim, S. H., Go, K. O., Ji, S. Y., Han, J. H., & Kim, C. Y. (2021). The combination PARP inhibitor olaparib with temozolomide in an experimental glioblastoma model. In Vivo, 35(4), 2015\u20132023. https:\/\/doi.org\/10.21873\/INVIVO.12470","journal-title":"In Vivo"},{"issue":"7","key":"2032_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-24-2974\/751359\/","volume":"31","author":"D Stefan","year":"2025","unstructured":"Stefan, D., Lesueur, P., Lequesne, J., Feuvret, L., Bronnimann, C., Cast\u00e9ra, M., & Clarisse, B. (2025). Olaparib, Temozolomide, and Concomitant Radiotherapy for Partially Resected or Biopsy-Only Glioblastoma First-Line Treatment: Results from the OLA-TMZ-RTE-01 Phase I Study. Clinical Cancer Research, 31(7), 1212\u20131222. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2974\/751359\/. https:\/\/AM\/OLAPARIB-TEMOZOLOMIDE-AND-CONCOMITANT-RADIOTHERAPY\"","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"2032_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/10717544.2019.1616235","volume":"26","author":"D Wang","year":"2019","unstructured":"Wang, D., Wang, C., Wang, L., & Chen, Y. (2019). A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain\/brain tumor barriers for glioblastoma treatment. Drug Delivery, 26(1), 551. https:\/\/doi.org\/10.1080\/10717544.2019.1616235","journal-title":"Drug Delivery"},{"key":"2032_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O Van Tellingen","year":"2015","unstructured":"Van Tellingen, O., Yetkin-Arik, B., De Gooijer, M. C., Wesseling, P., Wurdinger, T., & De Vries, H. E. (2015). Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates, 19, 1\u201312. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002","journal-title":"Drug Resistance Updates"},{"issue":"2","key":"2032_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/NEUONC\/NOX175","volume":"20","author":"JN Sarkaria","year":"2017","unstructured":"Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., & Elmquist, W. F. (2017). Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 20(2), 184. https:\/\/doi.org\/10.1093\/NEUONC\/NOX175","journal-title":"Neuro-Oncology"},{"issue":"6","key":"2032_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2174\/1871520615666150407155319","volume":"15","author":"M Ros","year":"2015","unstructured":"Ros, M., da, Iorio, A. L., Lucchesi, M., Stival, A., de Martino, M., & Sardi, I. (2015). The Use of Anthracyclines for Therapy of CNS Tumors. Anti-Cancer Agents in Medicinal Chemistry, 15(6), 721. https:\/\/doi.org\/10.2174\/1871520615666150407155319","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"1","key":"2032_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-53684-y","volume":"14:1","author":"ME Oraiopoulou","year":"2024","unstructured":"Oraiopoulou, M. E., Tzamali, E., Psycharakis, S. E., Tzedakis, G., Makatounakis, T., Manolitsi, K., & Sakkalis, V. (2024). The Temozolomide\u2013Doxorubicin paradox in Glioblastoma in vitro\u2013in silico preclinical drug-screening. Scientific Reports 2024, 14:1(1), 1\u201312. https:\/\/doi.org\/10.1038\/s41598-024-53684-y. 14.","journal-title":"Scientific Reports 2024"},{"issue":"7","key":"2032_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1166\/JBN.2016.2266","volume":"12","author":"WY Zhao","year":"2016","unstructured":"Zhao, W. Y., Zhang, C. X., Liu, L., Mu, L. M., Zeng, F., Ju, R. J., & Lu, W. L. (2016). Construction of functional targeting daunorubicin liposomes used for eliminating brain glioma and glioma stem cells. Journal of Biomedical Nanotechnology, 12(7), 1404\u20131420. https:\/\/doi.org\/10.1166\/JBN.2016.2266","journal-title":"Journal of Biomedical Nanotechnology"},{"key":"2032_CR17","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.2147\/IJN.S431409","volume":"18","author":"J Yang","year":"2023","unstructured":"Yang, J., Shang, J., Yang, L., Wei, D., Wang, X., Deng, Q., & Zhou, M. (2023). Nanotechnology-Based Drug Delivery Systems for Honokiol: Enhancing Therapeutic Potential and Overcoming Limitations. International Journal of Nanomedicine, 18, 6639. https:\/\/doi.org\/10.2147\/IJN.S431409","journal-title":"International Journal of Nanomedicine"},{"issue":"15","key":"2032_CR18","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.18632\/ONCOTARGET.2267","volume":"5","author":"XT Li","year":"2014","unstructured":"Li, X. T., Ju, R. J., Li, X. Y., Zeng, F., Shi, J. F., Liu, L., & Lu, W. L. (2014). Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. Oncotarget, 5(15), 6497\u20136511. https:\/\/doi.org\/10.18632\/ONCOTARGET.2267","journal-title":"Oncotarget"},{"key":"2032_CR19","doi-asserted-by":"publisher","unstructured":"Liu, S., Zhang, S. meng, Ju, R. jun, Xiao, Y., Wang, X., Song, X. li, \u2026 Chen, G.rong. (2017). Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. European Journal of Pharmaceutical Sciences, 106, 185\u2013197. https:\/\/doi.org\/10.1016\/j.ejps.2017.06.002.","DOI":"10.1016\/j.ejps.2017.06.002."},{"issue":"1","key":"2032_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/21691401.2020.1814314","volume":"49","author":"HJ Xie","year":"2021","unstructured":"Xie, H. J., Zhan-Dui, N. B., Zhao, J., Er-Bu, A. G. A., Zhen, P., ZhuoMa, D. Z., & Sang, T. (2021). Evaluation of nanoscaled dual targeting drug-loaded liposomes on inhibiting vasculogenic mimicry channels of brain glioma. Artificial Cells Nanomedicine and Biotechnology, 49(1), 596\u2013605. https:\/\/doi.org\/10.1080\/21691401.2020.1814314;SUBPAGE:STRING:FULL.","journal-title":"Artificial Cells Nanomedicine and Biotechnology"},{"issue":"JUN","key":"2032_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3389\/FNEUR.2018.00459","volume":"9","author":"A Mehta","year":"2018","unstructured":"Mehta, A., Awah, C. U., & Sonabend, A. M. (2018). Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy. Frontiers in Neurology, 9(JUN), 459. https:\/\/doi.org\/10.3389\/FNEUR.2018.00459","journal-title":"Frontiers in Neurology"},{"key":"2032_CR22","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.2147\/CMAR.S258584","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu, Y., Song, X., Wu, M., Wu, J., & Liu, J. (2020). Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications. Cancer Management and Research, 12, 8341. https:\/\/doi.org\/10.2147\/CMAR.S258584","journal-title":"Cancer Management and Research"},{"issue":"11","key":"2032_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/BIOMEDICINES9111562","volume":"9","author":"V Zoi","year":"2021","unstructured":"Zoi, V., Galani, V., Vartholomatos, E., Zacharopoulou, N., Tsoumeleka, E., Gkizas, G., & Alexiou, G. A. (2021). Curcumin and Radiotherapy Exert Synergistic Anti-Glioma Effect In Vitro. Biomedicines, 9(11), 1562. https:\/\/doi.org\/10.3390\/BIOMEDICINES9111562","journal-title":"Biomedicines"},{"issue":"2","key":"2032_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.FREERADBIOMED.2011.10.487","volume":"52","author":"CJ Lin","year":"2012","unstructured":"Lin, C. J., Lee, C. C., Shih, Y. L., Lin, T. Y., Wang, S. H., Lin, Y. F., & Shih, C. M. (2012). Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radical Biology and Medicine, 52(2), 377\u2013391. https:\/\/doi.org\/10.1016\/J.FREERADBIOMED.2011.10.487","journal-title":"Free Radical Biology and Medicine"},{"key":"2032_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/J.PHYMED.2018.06.012","volume":"49","author":"CC Chio","year":"2018","unstructured":"Chio, C. C., Tai, Y. T., Mohanraj, M., Liu, S. H., Yang, S. T., & Chen, R. M. (2018). Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway. Phytomedicine, 49, 41\u201351. https:\/\/doi.org\/10.1016\/J.PHYMED.2018.06.012","journal-title":"Phytomedicine"},{"issue":"2","key":"2032_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2010.11.008","volume":"302","author":"TC Chen","year":"2011","unstructured":"Chen, T. C., Wang, W., Golden, E. B., Thomas, S., Sivakumar, W., Hofman, F. M., & Sch\u00f6nthal, A. H. (2011). Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Letters, 302(2), 100\u2013108. https:\/\/doi.org\/10.1016\/j.canlet.2010.11.008","journal-title":"Cancer Letters"},{"issue":"10","key":"2032_CR27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/NEUONC\/NOY016","volume":"20","author":"S Choi","year":"2018","unstructured":"Choi, S., Yu, Y., Grimmer, M. R., Wahl, M., Chang, S. M., & Costello, J. F. (2018). Temozolomide-associated hypermutation in gliomas. Neuro-Oncology, 20(10), 1300. https:\/\/doi.org\/10.1093\/NEUONC\/NOY016","journal-title":"Neuro-Oncology"},{"key":"2032_CR28","doi-asserted-by":"publisher","unstructured":"Daniel, P., Meehan, B., Sabri, S., Jamali, F., Sarkaria, J. N., Choi, D., \u2026 Abdulkarim,B. (2022). Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neuro-Oncology Advances, 4(1). https:\/\/doi.org\/10.1093\/NOAJNL\/VDAC076.","DOI":"10.1093\/NOAJNL\/VDAC076."},{"key":"2032_CR29","doi-asserted-by":"publisher","unstructured":"Touat, M., Li, Y. Y., Boynton, A. N., Spurr, L. F., Iorgulescu, J. B., Bohrson, C.L., \u2026 Ligon, K. L. (2020). Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 580(7804), 517. https:\/\/doi.org\/10.1038\/S41586-020-2209-9.","DOI":"10.1038\/S41586-020-2209-9."},{"key":"2032_CR30","doi-asserted-by":"publisher","unstructured":"Qi, X., Jha, S. K., Jha, N. K., Dewanjee, S., Dey, A., Deka, R., \u2026 Hou, K. (2022). Antioxidants in brain tumors: current therapeutic significance and future prospects.Molecular Cancer 2022 21:1, 21(1), 1\u201332. https:\/\/doi.org\/10.1186\/S12943-022-01668-9","DOI":"10.1186\/S12943-022-01668-9"},{"key":"2032_CR31","doi-asserted-by":"publisher","unstructured":"Liu, S., Dong, L., Shi, W., Zheng, Z., Liu, Z., Meng, L., \u2026 Jiang, X. (2022). Potential targets and treatments affect oxidative stress in gliomas: An overview of molecular mechanisms. Frontiers in Pharmacology, 13, 921070. https:\/\/doi.org\/10.3389\/FPHAR.2022.921070.","DOI":"10.3389\/FPHAR.2022.921070."},{"key":"2032_CR32","doi-asserted-by":"publisher","first-page":"1428528","DOI":"10.3389\/FNUT.2024.1428528\/FULL","volume":"11","author":"YJ Ni","year":"2024","unstructured":"Ni, Y. J., Huang, Y. Q., Yu, L., Zhang, X. Y., Zhu, Q., Shu, L., & Zhang, L. (2024). Associations between dietary antioxidant vitamins and risk of glioma: an updated systematic review and meta-analysis of observational studies. Frontiers in Nutrition, 11, 1428528. https:\/\/doi.org\/10.3389\/FNUT.2024.1428528\/FULL","journal-title":"Frontiers in Nutrition"},{"key":"2032_CR33","doi-asserted-by":"publisher","first-page":"1077452","DOI":"10.3389\/FNUT.2022.1077452\/BIBTEX","volume":"9","author":"L Shu","year":"2023","unstructured":"Shu, L., Yu, D., & Jin, F. (2023). Healthy dietary patterns, foods, and risk of glioma: A systematic review and meta-analysis of observational studies. Frontiers in Nutrition, 9, 1077452. https:\/\/doi.org\/10.3389\/FNUT.2022.1077452\/BIBTEX","journal-title":"Frontiers in Nutrition"},{"issue":"10","key":"2032_CR34","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/CANCERS13102317","volume":"13","author":"K Zhai","year":"2021","unstructured":"Zhai, K., Siddiqui, M., Abdellatif, B., Liskova, A., Kubatka, P., & B\u00fcsselberg, D. (2021). Natural Compounds in Glioblastoma Therapy: Preclinical Insights, Mechanistic Pathways, and Outlook. Cancers, 13(10), 2317. https:\/\/doi.org\/10.3390\/CANCERS13102317","journal-title":"Cancers"},{"issue":"5","key":"2032_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/S00210-015-1096-3","volume":"388","author":"K Gach","year":"2015","unstructured":"Gach, K., D\u0142ugosz, A., & Janecka, A. (2015). The role of oxidative stress in anticancer activity of sesquiterpene lactones. Naunyn-Schmiedeberg\u2019s archives of pharmacology, 388(5), 477\u2013486. https:\/\/doi.org\/10.1007\/S00210-015-1096-3","journal-title":"Naunyn-Schmiedeberg\u2019s archives of pharmacology"},{"key":"2032_CR36","doi-asserted-by":"publisher","first-page":"1551115","DOI":"10.3389\/FPHAR.2025.1551115\/FULL","volume":"16","author":"J Li","year":"2025","unstructured":"Li, J., Li, X., & Liu, H. (2025). Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide. Frontiers in Pharmacology, 16, 1551115. https:\/\/doi.org\/10.3389\/FPHAR.2025.1551115\/FULL","journal-title":"Frontiers in Pharmacology"},{"key":"2032_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.20517\/CDR.2024.178","volume":"8","author":"C Teng","year":"2025","unstructured":"Teng, C., Chen, J. W., Shen, L. S., Chen, S., & Chen, G. Q. (2025). Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways. Cancer Drug Resistance, 8, 13. https:\/\/doi.org\/10.20517\/CDR.2024.178","journal-title":"Cancer Drug Resistance"},{"issue":"1","key":"2032_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/S10571-013-9991-Y","volume":"34","author":"H Turkez","year":"2013","unstructured":"Turkez, H., Sozio, P., Geyikoglu, F., Tatar, A., Hacimuftuoglu, A., & Di Stefano, A. (2013). Neuroprotective Effects of Farnesene Against Hydrogen Peroxide-Induced Neurotoxicity In vitro. Cellular and Molecular Neurobiology, 34(1), 101. https:\/\/doi.org\/10.1007\/S10571-013-9991-Y","journal-title":"Cellular and Molecular Neurobiology"},{"issue":"2","key":"2032_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3906\/biy-1309-55","volume":"38","author":"K \u00c7elik","year":"2014","unstructured":"\u00c7elik, K., To\u01e7ar, B., T\u00fcrkez, H., & Ta\u015fpinar, N. (2014). In vitro cytotoxic, genotoxic, and oxidative effects of acyclic sesquiterpene farnesene. Turkish Journal of Biology, 38(2), 253\u2013259. https:\/\/doi.org\/10.3906\/biy-1309-55","journal-title":"Turkish Journal of Biology"},{"key":"2032_CR40","unstructured":"Ma, J., & Motsinger-Reif, A. (2019). Current Methods for Quantifying Drug Synergism. Proteomics & bioinformatics: current research, 1(2), 43\u201348. Retrieved from http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32043089"},{"key":"2032_CR41","doi-asserted-by":"publisher","unstructured":"Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., \u2026 Singh, G. (2025).Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal Transduction and Targeted Therapy 2025 10:1, 10(1), 213. https:\/\/doi.org\/10.1038\/s41392-025-02299-4","DOI":"10.1038\/s41392-025-02299-4"},{"key":"2032_CR42","doi-asserted-by":"publisher","first-page":"e405525","DOI":"10.1590\/ACB405525","volume":"40","author":"GT G\u00fcrsoy","year":"2025","unstructured":"G\u00fcrsoy, G. T., Tuncer, M. C., & \u00d6zdemir, \u0130. (2025). Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway. Acta Cir\u00fargica Brasileira, 40, e405525. https:\/\/doi.org\/10.1590\/ACB405525","journal-title":"Acta Cir\u00fargica Brasileira"},{"key":"2032_CR43","doi-asserted-by":"publisher","unstructured":"Bagherian, A., Mardani, R., Roudi, B., Taghizadeh, M., Banfshe, H. R., Ghaderi, A.,\u2026 Mirzaei, H. (2020). Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways. Journal of Molecular Neuroscience 2020 70:10, 70(10), 1471\u20131483. https:\/\/doi.org\/10.1007\/S12031-020-01639-Z.","DOI":"10.1007\/S12031-020-01639-Z."},{"issue":"3","key":"2032_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/J.EJPB.2013.07.013","volume":"85","author":"F Dilnawaz","year":"2013","unstructured":"Dilnawaz, F., & Sahoo, S. K. (2013). Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. European Journal of Pharmaceutics and Biopharmaceutics, 85(3), 452\u2013462. https:\/\/doi.org\/10.1016\/J.EJPB.2013.07.013","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"2032_CR45","doi-asserted-by":"publisher","first-page":"156575","DOI":"10.1016\/J.PHYMED.2025.156575","volume":"140","author":"G Ke","year":"2025","unstructured":"Ke, G., Hu, P., Xiong, H., Zhang, J., Xu, H., Xiao, C., & Zheng, Q. (2025). Enhancing temozolomide efficacy in GBM: The synergistic role of chuanxiong rhizoma essential oil. Phytomedicine, 140, 156575. https:\/\/doi.org\/10.1016\/J.PHYMED.2025.156575","journal-title":"Phytomedicine"},{"issue":"12","key":"2032_CR46","doi-asserted-by":"publisher","first-page":"14324","DOI":"10.3390\/CIMB46120859","volume":"46","author":"L Gaiaschi","year":"2024","unstructured":"Gaiaschi, L., Bottone, M. G., & De Luca, F. (2024). Towards Effective Treatment of Glioblastoma: The Role of Combination Therapies and the Potential of Phytotherapy and Micotherapy. Current Issues in Molecular Biology 2024, 46(12), 14324\u201314350. https:\/\/doi.org\/10.3390\/CIMB46120859. 46.","journal-title":"Current Issues in Molecular Biology 2024"},{"key":"2032_CR47","doi-asserted-by":"publisher","first-page":"114477","DOI":"10.1016\/J.BIOPHA.2023.114477","volume":"161","author":"X Liu","year":"2023","unstructured":"Liu, X., Xiao, X., Han, X., Yao, L., & Lan, W. (2023). Natural flavonoids alleviate glioblastoma multiforme by regulating long non-coding RNA. Biomedicine & Pharmacotherapy, 161, 114477. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114477","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2032_CR48","doi-asserted-by":"publisher","unstructured":"Ayaz, M., Nawaz, A., Ahmad, S., Mosa, O. F., Eisa Hamdoon, A. A., Khalifa, M. A.,\u2026 Ananda Murthy, H. C. (2022). Underlying Anticancer Mechanisms and Synergistic Combinations of Phytochemicals with Cancer Chemotherapeutics: Potential Benefits and Risks. Journal of Food Quality, 2022(1), 1189034. https:\/\/doi.org\/10.1155\/2022\/1189034.","DOI":"10.1155\/2022\/1189034."},{"issue":"6","key":"2032_CR49","doi-asserted-by":"publisher","first-page":"e09519","DOI":"10.1016\/J.HELIYON.2022.E09519","volume":"8","author":"AM Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda, A. M., Mel\u00e9ndez, C. M., Uribe, D., & Pedroza-D\u00edaz, J. (2022). Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies. Heliyon, 8(6), e09519. https:\/\/doi.org\/10.1016\/J.HELIYON.2022.E09519","journal-title":"Heliyon"},{"key":"2032_CR50","doi-asserted-by":"publisher","unstructured":"Deniz, S., & Chaachouay, N. (2025). Synergy, Additive Effects, and Antagonism of Drugs with Plant Bioactive Compounds. Drugs and Drug Candidates 2025, Vol. 4, Page 4, 4(1), 4. https:\/\/doi.org\/10.3390\/DDC4010004","DOI":"10.3390\/DDC4010004"},{"issue":"7","key":"2032_CR51","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/MOLECULES29071682","volume":"29","author":"A Majchrzak-Celi\u0144ska","year":"2024","unstructured":"Majchrzak-Celi\u0144ska, A., & Studzi\u0144ska-Sroka, E. (2024). New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy. Molecules 2024, 29(7), 1682. https:\/\/doi.org\/10.3390\/MOLECULES29071682. 29.","journal-title":"Molecules 2024"},{"issue":"1","key":"2032_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/S44178-025-00208-X","volume":"2025 4:1","author":"AH El-Far","year":"2025","unstructured":"El-Far, A. H., Elfadadny, A., Ragab, R. F., Hamada, R., Elbadawy, M., & Fu, J. (2025). Combination of approved chemotherapeutics and natural products for topoisomerase II targeting: efficacy and safety in cancer therapy. Holistic Integrative Oncology, 2025 4:1(1), 69. https:\/\/doi.org\/10.1007\/S44178-025-00208-X. 4.","journal-title":"Holistic Integrative Oncology"},{"issue":"2","key":"2032_CR53","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bjp.2015.02.009","volume":"25","author":"PF de Oliveira","year":"2015","unstructured":"de Oliveira, P. F., Alves, J. M., Damasceno, J. L., Oliveira, R. A. M., J\u00fanior Dias, H., Crotti, A. E. M., & Tavares, D. C. (2015). Cytotoxicity screening of essential oils in cancer cell lines. Revista Brasileira de Farmacognosia, 25(2), 183\u2013188. https:\/\/doi.org\/10.1016\/j.bjp.2015.02.009","journal-title":"Revista Brasileira de Farmacognosia"},{"issue":"2","key":"2032_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.35378\/gujs.1521580","volume":"38","author":"BM Omirkhanovna","year":"2025","unstructured":"Omirkhanovna, B. M., Servi, H., Barak, T. H., Ertekin, S. K. A. R. A., & Toleppekovna, N. S. (2025). Cytotoxic Activity of Root, Stem, and Flower Essential Oils from Ferula tenuisecta Korovin. Gazi University Journal of Science, 38(2), 549\u2013558. https:\/\/doi.org\/10.35378\/gujs.1521580","journal-title":"Gazi University Journal of Science"},{"issue":"2","key":"2032_CR55","doi-asserted-by":"publisher","first-page":"144","DOI":"10.25135\/rnp.143.19.05.1291","volume":"14","author":"M Tian","year":"2019","unstructured":"Tian, M., Hong, Y., Wu, X., Zhang, M., Lin, B., & Zho, Y. (2019). Chemical constituents and cytotoxic activities of essential oils from the flowers, leaves and stems of Zingiber striolatum diels. Records of Natural Products, 14(2), 144\u2013149. https:\/\/doi.org\/10.25135\/rnp.143.19.05.1291","journal-title":"Records of Natural Products"},{"key":"2032_CR56","doi-asserted-by":"publisher","unstructured":"Tomko, A. M., Whynot, E. G., Ellis, L. D., & Dupr\u00e9, D. J. (2020). Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. Cancers 2020, Vol. 12, Page 1985, 12(7), 1985. https:\/\/doi.org\/10.3390\/CANCERS12071985","DOI":"10.3390\/CANCERS12071985"},{"key":"2032_CR57","doi-asserted-by":"publisher","unstructured":"Jamshidi, N., Mojarrab, M., Delnavazi, M.-R., Emami, A., Bahrami, G., Shokoohinia,Y., \u2026 Hosseinzadeh, L. (2024). Cytotoxic Activity and Phytochemical Analysis of Artemisia biennis Essential Oils at Different Growth Stages. Jundishapur Journal of Natural Pharmaceutical Products 2024 19:4, 19(4), e147988. https:\/\/doi.org\/10.5812\/JJNPP-147988.","DOI":"10.5812\/JJNPP-147988."},{"issue":"1","key":"2032_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/1735-5362.278712","volume":"15","author":"A Abbasi","year":"2020","unstructured":"Abbasi, A., Hajialyani, M., Hosseinzadeh, L., Jalilian, F., Yaghmaei, P., Navid, S. J., & Motamed, H. (2020). Evaluation of the cytotoxic and apoptogenic effects of cinnamaldehyde on U87MG cells alone and in combination with doxorubicin. Research in Pharmaceutical Sciences, 15(1), 26. https:\/\/doi.org\/10.4103\/1735-5362.278712","journal-title":"Research in Pharmaceutical Sciences"},{"issue":"4","key":"2032_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/J.TIPS.2020.01.011","volume":"41","author":"CT Meyer","year":"2020","unstructured":"Meyer, C. T., Wooten, D. J., Lopez, C. F., & Quaranta, V. (2020). Charting the fragmented landscape of drug synergy. Trends in pharmacological sciences, 41(4), 266. https:\/\/doi.org\/10.1016\/J.TIPS.2020.01.011","journal-title":"Trends in pharmacological sciences"},{"key":"2032_CR60","doi-asserted-by":"publisher","unstructured":"Wooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021). MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nature Communications, 12(1). https:\/\/doi.org\/10.1038\/S41467-021-24789-Z","DOI":"10.1038\/S41467-021-24789-Z"},{"key":"2032_CR61","doi-asserted-by":"publisher","unstructured":"Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover,D., \u2026 Quaranta, V. (2019). Quantifying Drug Combination Synergy along Potency and Efficacy Axes. Cell Systems, 8(2), 97\u2013108.e16. https:\/\/doi.org\/10.1016\/J.CELS.2019.01.003.","DOI":"10.1016\/J.CELS.2019.01.003."},{"issue":"4","key":"2032_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/S00280-022-04469-5","volume":"90","author":"AS Karve","year":"2022","unstructured":"Karve, A. S., Desai, J. M., Dave, N., Wise-Draper, T. M., Gudelsky, G. A., Phoenix, T. N., & Desai, P. B. (2022). Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. Cancer Chemotherapy and Pharmacology, 90(4), 345\u2013356. https:\/\/doi.org\/10.1007\/S00280-022-04469-5","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"19","key":"2032_CR63","doi-asserted-by":"publisher","first-page":"2309290","DOI":"10.1002\/ADVS.202309290","volume":"11","author":"Q Yue","year":"2024","unstructured":"Yue, Q., Wang, Z., Shen, Y., Lan, Y., Zhong, X., Luo, X., & Guo, H. (2024). Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. Advanced Science, 11(19), 2309290. https:\/\/doi.org\/10.1002\/ADVS.202309290. PAGEGROUP:STRING:PUBLICATION.","journal-title":"Advanced Science"},{"issue":"13(1)","key":"2032_CR64","doi-asserted-by":"publisher","first-page":"21835","DOI":"10.1038\/s41598-023-48777-z","volume":"13:1","author":"S Zhu","year":"2023","unstructured":"Zhu, S., Guo, J., Yu, L., Liu, J., Chen, J., Xin, J., & Duan, C. (2023). Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells. Scientific Reports 2023, 13:1(13(1)), 21835. https:\/\/doi.org\/10.1038\/s41598-023-48777-z","journal-title":"Scientific Reports 2023"},{"key":"2032_CR65","doi-asserted-by":"publisher","unstructured":"Kamani, M., Ghanbari, A., Taghadosi, M., Mansouri, K., Jalili, C., Kamani, M., \u2026Jalili, C. (2022). Harmine Augments the Cytotoxic and Anti-invasive Potential of Temozolomide Against Glioblastoma Multiforme Cells. Jundishapur Journal of Natural Pharmaceutical Products 2022 17:2, 17(2), e115464. https:\/\/doi.org\/10.5812\/JJNPP.115464.","DOI":"10.5812\/JJNPP.115464."},{"key":"2032_CR66","doi-asserted-by":"publisher","first-page":"1643186","DOI":"10.3389\/FPHAR.2025.1643186\/BIBTEX","volume":"16","author":"Y Aks\u00fct","year":"2025","unstructured":"Aks\u00fct, Y., \u015eengelen, A., G\u00fcrsoy, D. M., \u00d6\u011f\u00fctc\u00fc, \u0130., Kuvet, \u00d6., & Pekmez, M. (2025). Chrysin sensitizes glioblastoma cells and spheroids to temozolomide treatment by reducing EMT and stemness phenotypes, as well as targeting multidrug resistance proteins. Frontiers in Pharmacology, 16, 1643186. https:\/\/doi.org\/10.3389\/FPHAR.2025.1643186\/BIBTEX","journal-title":"Frontiers in Pharmacology"},{"issue":"12","key":"2032_CR67","doi-asserted-by":"publisher","first-page":"e75047","DOI":"10.7759\/CUREUS.75047","volume":"16","author":"E Sarkar","year":"2024","unstructured":"Sarkar, E., Khan, A., Ahmad, R., Misra, A., Raza, S. T., & Mahdi, A. A. (2024). Synergistic Anticancer Efficacy of Curcumin and Doxorubicin Combination Treatment Inducing S-phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells: An In Vitro Study. Cureus, 16(12), e75047. https:\/\/doi.org\/10.7759\/CUREUS.75047","journal-title":"Cureus"},{"issue":"1","key":"2032_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/S43046-023-00166-3","volume":"35:1","author":"ND Amalina","year":"2023","unstructured":"Amalina, N. D., Salsabila, I. A., Zulfin, U. M., Jenie, R. I., & Meiyanto, E. (2023). In vitro synergistic effect of hesperidin and doxorubicin downregulates epithelial-mesenchymal transition in highly metastatic breast cancer cells. Journal of the Egyptian National Cancer Institute 2023, 35:1(1), 6. https:\/\/doi.org\/10.1186\/S43046-023-00166-3. 35.","journal-title":"Journal of the Egyptian National Cancer Institute 2023"},{"issue":"13","key":"2032_CR69","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3390\/CANCERS13133299\/S1","volume":"13","author":"G Lohiya","year":"2021","unstructured":"Lohiya, G., & Katti, D. S. (2021). A synergistic combination of niclosamide and doxorubicin as an efficacious therapy for all clinical subtypes of breast cancer. Cancers, 13(13), 3299. https:\/\/doi.org\/10.3390\/CANCERS13133299\/S1","journal-title":"Cancers"},{"issue":"2","key":"2032_CR70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/physiologia3020013","volume":"3","author":"S Banerjee","year":"2023","unstructured":"Banerjee, S., & Banerjee, S. (2023). Anticancer Potential and Molecular Mechanisms of Cinnamaldehyde and Its Congeners Present in the Cinnamon Plant. Physiologia, 3(2), 173\u2013207. https:\/\/doi.org\/10.3390\/physiologia3020013","journal-title":"Physiologia"},{"issue":"1","key":"2032_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/MMR.2022.12898\/HTML","volume":"27","author":"D Hu","year":"2023","unstructured":"Hu, D., Meng, R. Y., van Nguyen, T., Chai, O. H., Park, B. H., Lee, J. S., & Kim, S. M. (2023). Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway. Molecular Medicine Reports, 27(1), 1\u201318. https:\/\/doi.org\/10.3892\/MMR.2022.12898\/HTML","journal-title":"Molecular Medicine Reports"},{"issue":"10","key":"2032_CR72","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/BIOMEDICINES9101353","volume":"9","author":"WH Talib","year":"2021","unstructured":"Talib, W. H., Alsayed, A. R., Barakat, M., Abu-Taha, M. I., & Mahmod, A. I. (2021). Targeting Drug Chemo-Resistance in Cancer Using Natural Products. Biomedicines, 9(10), 1353. https:\/\/doi.org\/10.3390\/BIOMEDICINES9101353","journal-title":"Biomedicines"},{"issue":"2","key":"2032_CR73","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/NEUONC\/NOX175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., & Elmquist, W. F. (2018). Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-oncology, 20(2), 184\u2013191. https:\/\/doi.org\/10.1093\/NEUONC\/NOX175","journal-title":"Neuro-oncology"},{"key":"2032_CR74","doi-asserted-by":"publisher","unstructured":"Van Tellingen, O., Yetkin-Arik, B., De Gooijer, M. C., Wesseling, P., Wurdinger, T., & De Vries, H. E. (2015, March 1). Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates. Drug Resist Updat. https:\/\/doi.org\/10.1016\/j.drup.2015.02.002","DOI":"10.1016\/j.drup.2015.02.002"},{"issue":"2","key":"2032_CR75","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/S002800050964","volume":"44","author":"M Zucchetti","year":"1999","unstructured":"Zucchetti, M., Boiardi, A., Silvani, A., Parisi, I., Piccolrovazzi, S., & D\u2019Incalci, M. (1999). Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer chemotherapy and pharmacology, 44(2), 173\u2013176. https:\/\/doi.org\/10.1007\/S002800050964","journal-title":"Cancer chemotherapy and pharmacology"},{"issue":"2","key":"2032_CR76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/J.JCONREL.2009.09.020","volume":"141","author":"X Ying","year":"2010","unstructured":"Ying, X., Wen, H., Lu, W. L., Du, J., Guo, J., Tian, W., & Zhang, Q. (2010). Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. Journal of controlled release: official journal of the Controlled Release Society, 141(2), 183\u2013192. https:\/\/doi.org\/10.1016\/J.JCONREL.2009.09.020","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"2032_CR77","doi-asserted-by":"publisher","unstructured":"Rolfe, N. W., Dadario, N. B., Canoll, P., & Bruce, J. N. (2024). A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma. Pharmaceuticals (Basel Switzerland), 17(8). https:\/\/doi.org\/10.3390\/PH17080973","DOI":"10.3390\/PH17080973"},{"key":"2032_CR78","doi-asserted-by":"publisher","unstructured":"Liu, S., Zhang, S. meng, Ju, R. jun, Xiao, Y., Wang, X., Song, X. li, \u2026 Chen, G.rong. (2017). Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, 106, 185\u2013197. https:\/\/doi.org\/10.1016\/J.EJPS.2017.06.002.","DOI":"10.1016\/J.EJPS.2017.06.002."},{"issue":"1","key":"2032_CR79","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1038\/s41467-021-24789-z","volume":"12:1","author":"DJ Wooten","year":"2021","unstructured":"Wooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021). MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery. Nature Communications 2021, 12:1(1), 4607. https:\/\/doi.org\/10.1038\/s41467-021-24789-z. 12.","journal-title":"Nature Communications 2021"},{"issue":"4","key":"2032_CR80","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.bbrc.2020.10.058","volume":"533","author":"B Goker Bagca","year":"2020","unstructured":"Goker Bagca, B., Ozates, N. P., Asik, A., Caglar, H. O., Gunduz, C., & Avci, B., C (2020). Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells. Biochemical and Biophysical Research Communications, 533(4), 1497\u20131504. https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.058","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"23","key":"2032_CR81","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/ONCOTARGET.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017). Combination therapy in combating cancer. Oncotarget, 8(23), 38022. https:\/\/doi.org\/10.18632\/ONCOTARGET.16723","journal-title":"Oncotarget"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02032-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:23:07Z","timestamp":1780482187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02032-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02032-0","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"15 February 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}